Open letter to President Trump from biopharma innovators, investors, and patient advocates regarding proposed FDA budget and personnel cuts.

Advocacy
Written By Marshall Bursis
Marshall Bursis
Previous

Consumers sound alarm: state price controls will limit access without lowering patient costs
Next

Defending the NIH, the NSF, and the foundation of American science